$KPTI 8-K SEC Filings

As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indenture...

As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10,...

On September 17, 2026, the Pricing Committee of the Board of Directors of Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), acting pursuant to authority delegated to it by the Board of Directors on September 10, 2026 ...

This Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026 (this “Agreement”), is entered into by and among (i) Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”) and each of the undersi...